162 related articles for article (PubMed ID: 31839603)
1. Predictive value of unmethylated RASSF1A on disease progression in non-small cell lung cancer patients receiving pemetrexed-based chemotherapy.
Deng Q; Su B; Ji X; Fang Q; Zhou S; Zhou C
Cancer Biomark; 2020; 27(3):313-323. PubMed ID: 31839603
[TBL] [Abstract][Full Text] [Related]
2. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
de Fraipont F; Levallet G; Creveuil C; Bergot E; Beau-Faller M; Mounawar M; Richard N; Antoine M; Rouquette I; Favrot MC; Debieuvre D; Braun D; Westeel V; Quoix E; Brambilla E; Hainaut P; Moro-Sibilot D; Morin F; Milleron B; Zalcman G;
Clin Cancer Res; 2012 May; 18(10):2976-86. PubMed ID: 22434665
[TBL] [Abstract][Full Text] [Related]
3. Methylation analysis of SHOX2 and RASSF1A in bronchoalveolar lavage fluid for early lung cancer diagnosis.
Ren M; Wang C; Sheng D; Shi Y; Jin M; Xu S
Ann Diagn Pathol; 2017 Apr; 27():57-61. PubMed ID: 28325362
[No Abstract] [Full Text] [Related]
4. [Meta-analysis of the Association between RASSF1A Gene Promoter Methylation and Non-small Cell Lung Cancer].
Wei H; Fang N; Guo L; Wu Z; Zhou Q
Zhongguo Fei Ai Za Zhi; 2015 Jul; 18(7):443-50. PubMed ID: 26182870
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis.
Wang J; Wang B; Chen X; Bi J
Carcinogenesis; 2011 Mar; 32(3):411-6. PubMed ID: 21156971
[TBL] [Abstract][Full Text] [Related]
7. Methylation of RASSF1A and CDH13 genes in individualized chemotherapy for patients with non-small cell lung cancer.
Zhai X; Li SJ
Asian Pac J Cancer Prev; 2014; 15(12):4925-8. PubMed ID: 24998565
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of methylation status of RASSF1A gene as an independent factor of non-small cell lung cancer].
Zhang H; Zhang S; Zhang Z; Jia H; Gu S; Zhao D
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):311-6. PubMed ID: 20677556
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of RASSF1A methylation status in non-small cell lung cancer (NSCLC) patients: A meta-analysis of prospective studies.
Hu H; Zhou Y; Zhang M; Ding R
Biomarkers; 2019 May; 24(3):207-216. PubMed ID: 30764677
[No Abstract] [Full Text] [Related]
10. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J
Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308
[TBL] [Abstract][Full Text] [Related]
11. Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer.
Li N; Zeng Y; Huang J
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1379-1393. PubMed ID: 32266538
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients.
Dietrich D; Hasinger O; Liebenberg V; Field JK; Kristiansen G; Soltermann A
Diagn Mol Pathol; 2012 Jun; 21(2):93-104. PubMed ID: 22555092
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of mRNA expression levels and DNA methylation profiles of three neighboring genes: FUS1, NPRL2/G21 and RASSF1A in non-small cell lung cancer patients.
Pastuszak-Lewandoska D; Kordiak J; Migdalska-Sęk M; Czarnecka KH; Antczak A; Górski P; Nawrot E; Kiszałkiewicz JM; Domańska D; Brzeziańska-Lasota E
Respir Res; 2015 Jun; 16(1):76. PubMed ID: 26112163
[TBL] [Abstract][Full Text] [Related]
14. KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.
Park S; Kim JY; Lee SH; Suh B; Keam B; Kim TM; Kim DW; Heo DS
Korean J Intern Med; 2017 May; 32(3):514-522. PubMed ID: 28407465
[TBL] [Abstract][Full Text] [Related]
15. Promoter Methylation of RASSF1A indicates Prognosis for Patients with Stage II and III Colorectal Cancer Treated with Oxaliplatin-Based Chemotherapy.
Sun X; Yuan W; Hao F; Zhuang W
Med Sci Monit; 2017 Nov; 23():5389-5395. PubMed ID: 29128865
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine.
Fischer JR; Ohnmacht U; Rieger N; Zemaitis M; Stoffregen C; Manegold C; Lahm H
Lung Cancer; 2007 Apr; 56(1):115-23. PubMed ID: 17196704
[TBL] [Abstract][Full Text] [Related]
18. Associations between RASSF1A promoter methylation and NSCLC: a meta-analysis of published data.
Liu WJ; Tan XH; Guo BP; Ke Q; Sun J; Cen H
Asian Pac J Cancer Prev; 2013; 14(6):3719-24. PubMed ID: 23886171
[TBL] [Abstract][Full Text] [Related]
19. Thyroid transcription factor-1 expression in advanced non- small cell lung cancer: impact on survival outcome.
Elsamany SA; Al-Fayea TM; Alzahrani AS; Abozeed WN; Darwish W; Farooq MU; Almadani AS; Bukhari EA
Asian Pac J Cancer Prev; 2015; 16(7):2987-91. PubMed ID: 25854394
[TBL] [Abstract][Full Text] [Related]
20. High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.
Hashemi Sadraei N; Feng Y; Du L; Fu P; Haque S; Dowlati A; Gollamudi J; Pennell NA; Mekhail T; Avril S; Farver C; Gerson SL; Sharma N
Lung Cancer; 2018 Dec; 126():48-54. PubMed ID: 30527192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
